NCT03306472View on ClinicalTrials.gov

A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2023

Conditions

Breast Cancer

Interventions

DRUG

Megestrol Acetate 40 MG

Progesterone Agonist

DRUG

Megestrol Acetate 160 MG

Progesterone Agonist

DRUG

Letrozole

Aromatase Inhibitor

Trial Locations (1)

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

All Listed Sponsors

collaborator

Anticancer Fund, Belgium

OTHER

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT03306472 - A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer | Biotech Hunter | Biotech Hunter